Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-MS-A51U-01A-31R-A266-07

— · A

eb323442-2b6b-5007-a873-c49907528070

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A
overall_survival_months
23

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
  • ESTROGEN_RESPONSE_EARLY+0.360
  • WNT_BETA_CATENIN_SIGNALING+0.340
  • MYOGENESIS+0.330
  • APICAL_JUNCTION+0.320
  • ANGIOGENESIS+0.300
  • UV_RESPONSE_DN+0.300
  • APICAL_SURFACE+0.230
  • NOTCH_SIGNALING+0.230
  • ESTROGEN_RESPONSE_LATE+0.140

Top 10 suppressed

  • E2F_TARGETS-0.690
  • G2M_CHECKPOINT-0.610
  • MYC_TARGETS_V1-0.580
  • MYC_TARGETS_V2-0.490
  • MTORC1_SIGNALING-0.480
  • UNFOLDED_PROTEIN_RESPONSE-0.370
  • DNA_REPAIR-0.330
  • GLYCOLYSIS-0.290
  • CHOLESTEROL_HOMEOSTASIS-0.280
  • PROTEIN_SECRETION-0.280

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-HN-A2OB-01A-21R-A27Q-07
breast-umap@18
—A0.886
2SRR8613732
breast-umap@18
—A0.884
320050037.TNBC
breast-umap@18
—C0.878
4TCGA-EW-A1IX-01A-12R-A144-07
breast-umap@18
—A0.875
5SRR1382570
brain-umap@2
GTEX—0.872
6TCGA-A2-A4RY-01A-31R-A266-07
breast-umap@18
—A0.868
7TCGA-CN-6016-01A-11R-1686-07
head-neck@1
——0.868
8TCGA-IQ-A61J-01A-11R-A30B-07
head-neck@1
——0.867
9TCGA-AC-A8OS-01A-12R-A41B-07
breast-umap@18
—A0.866
10X9cad7a78.ea9b.47b0.9d06.e5e696031cc3
lung-landscapes@6
—cohortA10.864

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.380Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.360Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.340Inavolisib— uncovered
MYOGENESIS0.330Inavolisib— uncovered
APICAL_JUNCTION0.320Inavolisib— uncovered
ANGIOGENESIS0.300Remibrutinib— uncovered
UV_RESPONSE_DN0.300Inavolisib— uncovered
APICAL_SURFACE0.230Temsirolimus— uncovered
NOTCH_SIGNALING0.230Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.140Idelalisib— uncovered
HEDGEHOG_SIGNALING0.140Inavolisib— uncovered
KRAS_SIGNALING_DN0.140Remibrutinib— uncovered
COAGULATION0.130Binimetinib— uncovered
TGF_BETA_SIGNALING0.110Inavolisib— uncovered
BILE_ACID_METABOLISM0.090Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.090Inavolisib— uncovered
HYPOXIA0.060Idelalisib— uncovered
P53_PATHWAY0.050Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.040Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.030Inavolisib— uncovered